Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD)
- PMID: 20112369
- DOI: 10.1002/path.2677
Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD)
Abstract
In a substantial number of patients with systemic mastocytosis (SM), an associated clonal haematological non-mast cell lineage disease (AHNMD) is detectable. Although most of these patients display KIT mutations, especially KIT(D816V), little is known about their exact frequency and their distribution in AHNMD subtypes. We examined 48 patients with SM-AHNMD for the presence of mutant KIT in the SM and AHNMD components of the disease. Mast cells and AHNMD cells were obtained from immunostained bone marrow sections by laser microdissection and examined by melting point analysis of nested-PCR products. KIT(D816V) was found in AHNMD cells in the vast majority of patients with SM-chronic myelomonocytic leukaemia (CMML, 89%). Unexpectedly, KIT(D816V) was far less frequently detectable in AHNMD cells in patients with SM-myeloproliferative neoplasm (MPN, 20%) and SM-acute myeloid leukaemia (AML, 30%). None of the patients with lymphoproliferative AHNMDs displayed KIT codon 816 mutations in AHNMD cells (0/8). In FIP1L1/PDGFRA-positive chronic eosinophilic leukaemia (CEL), neither the SM nor the CEL component of the disease exhibited the KIT mutation. Our findings demonstrate that KIT codon 816 mutations are variably present in AHNMD cells in patients with SM-AHNMD, depending on the subtype of AHNMD. The high frequency of KIT(D816V) in neoplastic mast cells and leukaemic myelomonocytic cells in SM-CMML may point to a common precursor in these patients, and may have implications for the biology of the disease and the development of KIT-targeting therapies.
Copyright (c) 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Similar articles
-
Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.J Mol Diagn. 2008 Jan;10(1):58-66. doi: 10.2353/jmoldx.2008.070061. Epub 2007 Dec 28. J Mol Diagn. 2008. PMID: 18165278 Free PMC article.
-
KIT(D816V+) systemic mastocytosis associated with KIT(D816V+) acute erythroid leukaemia: first case report with molecular evidence for same progenitor cell derivation.J Clin Pathol. 2009 Dec;62(12):1147-9. doi: 10.1136/jcp.2009.067876. Epub 2009 Sep 2. J Clin Pathol. 2009. PMID: 19729359
-
Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations.Am J Hematol. 2003 May;73(1):12-7. doi: 10.1002/ajh.10322. Am J Hematol. 2003. PMID: 12701114
-
Mastocytosis.Novartis Found Symp. 2005;271:232-42; discussion 242-9. Novartis Found Symp. 2005. PMID: 16605139 Review.
-
Systemic mastocytosis with associated clonal hematologic nonmast cell lineage disease: a clinicopathologic review.Arch Pathol Lab Med. 2012 Jul;136(7):832-8. doi: 10.5858/arpa.2011-0325-RS. Arch Pathol Lab Med. 2012. PMID: 22742558 Review.
Cited by
-
[Mastocytosis and eosinophilic leukemia: diagnostics and classification].Pathologe. 2012 Nov;33(6):539-52. doi: 10.1007/s00292-012-1654-0. Pathologe. 2012. PMID: 23085697 German.
-
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.Leukemia. 2016 Jan;30(1):136-43. doi: 10.1038/leu.2015.284. Epub 2015 Oct 14. Leukemia. 2016. PMID: 26464169
-
Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee.Leukemia. 2024 Apr;38(4):699-711. doi: 10.1038/s41375-024-02182-1. Epub 2024 Mar 12. Leukemia. 2024. PMID: 38472477 Review.
-
ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.PLoS One. 2014 Jan 21;9(1):e85362. doi: 10.1371/journal.pone.0085362. eCollection 2014. PLoS One. 2014. PMID: 24465546 Free PMC article.
-
An adult patient with systemic mastocytosis and B-acute lymphoblastic leukemia.Case Rep Med. 2014;2014:526129. doi: 10.1155/2014/526129. Epub 2014 Nov 6. Case Rep Med. 2014. PMID: 25431599 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous